111 related articles for article (PubMed ID: 33284659)
1. Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer.
Jiang B; Zhou L; Lu J; Wang Y; Liu C; Zhou W; Guo J
Scand J Gastroenterol; 2021 Jan; 56(1):59-67. PubMed ID: 33284659
[TBL] [Abstract][Full Text] [Related]
2. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
3. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma.
Jiang B; Zhou L; Lu J; Wang Y; Liu C; Liang Z; Zhou W; You L; Guo J
J Gastroenterol Hepatol; 2021 Feb; 36(2):507-515. PubMed ID: 32875609
[TBL] [Abstract][Full Text] [Related]
5. Vav3 is linked to poor prognosis of pancreatic cancers and promotes the motility and invasiveness of pancreatic cancer cells.
Tsuboi M; Taniuchi K; Furihata M; Naganuma S; Kimura M; Watanabe R; Shimizu T; Saito M; Dabanaka K; Hanazaki K; Saibara T
Pancreatology; 2016; 16(5):905-16. PubMed ID: 27453460
[TBL] [Abstract][Full Text] [Related]
6. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
7. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
[TBL] [Abstract][Full Text] [Related]
8. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.
Fukushima H; Yasumoto M; Ogasawara S; Akiba J; Kitasato Y; Nakayama M; Naito Y; Ishida Y; Okabe Y; Yasunaga M; Horiuchi H; Sakamoto E; Itadani H; Mizuarai S; Oie S; Yano H
Mol Cancer; 2016 May; 15(1):32. PubMed ID: 27145964
[TBL] [Abstract][Full Text] [Related]
9. Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Li J; Hu G; Kong F; Wu K; Song K; He J; Sun W
Pathol Oncol Res; 2015 Sep; 21(4):1013-20. PubMed ID: 25791566
[TBL] [Abstract][Full Text] [Related]
10. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Liu XD; Zhang ZW; Wu HW; Liang ZY
Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
[TBL] [Abstract][Full Text] [Related]
11. High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.
Li H; Li X; Lin H; Gong J
Mol Med Rep; 2020 Feb; 21(2):822-832. PubMed ID: 31974610
[TBL] [Abstract][Full Text] [Related]
12. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
13. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
14. TIAM2 enhances non-small cell lung cancer cell invasion and motility.
Zhao ZY; Han CG; Liu JT; Wang CL; Wang Y; Cheng LY
Asian Pac J Cancer Prev; 2013; 14(11):6305-9. PubMed ID: 24377522
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
16. A potential prognostic marker and therapeutic target: SPOCK1 promotes the proliferation, metastasis, and apoptosis of pancreatic ductal adenocarcinoma cells.
Li J; Ke J; Fang J; Chen JP
J Cell Biochem; 2020 Jan; 121(1):743-754. PubMed ID: 31478239
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
[TBL] [Abstract][Full Text] [Related]
18. High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro.
Wang S; Li J; You L; Dai M; Zhao Y
Med Sci Monit; 2020 Oct; 26():e926432. PubMed ID: 33051432
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
20. Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma.
Huang Y; Ren GP; Xu C; Dong SF; Wang Y; Gan Y; Zhu L; Feng TY
BMC Cancer; 2014 Jul; 14():479. PubMed ID: 24989027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
